Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Renalytix (LSE:RENX): Aim-listed Shares in Focus as Unaudited Annual Financial Report Reshapes Investor Questions

Renalytix (LSE:RENX) is drawing attention following a company announcement dated 28 October 2026 concerning unaudited annual financial report. The diagnostics company published an unaudited report covering the twelve months ended 30 June 2026. This is a specific corporate development rather than evidence, by itself, …

Ankur Sharma | 29 October 2026

Sareum Holdings (LSE:SAR): Aim-listed Shares in Focus as Retail Offer Outcome Reshapes Investor Questions

Sareum Holdings (LSE:SAR) is drawing attention following a company announcement dated 28 October 2026 concerning retail offer outcome. The biotechnology company announced results of its WRAP offer. This is a specific corporate development rather than evidence, by itself, of a sustained change in market …

Ankur Sharma | 29 October 2026

GSK (LSE:GSK): What the Latest Results Could Mean for Investors

Investors are assessing how company-specific execution could influence earnings quality and future valuation.

Ankur Sharma | 29 October 2026

Haleon (LSE:HLN): What the Latest Corporate Update Could Mean for Investors

Investors are assessing how company-specific execution could influence earnings quality and future valuation.

Ankur Sharma | 29 October 2026

Renalytix (LSE:RENX) cuts operating loss to $14.0m ahead of Q1 2027 US national launch with Quest

On 28 October 2026, Renalytix plc, listed in London as RENX, published unaudited results for the twelve months to 30 June 2026. The figures have been prepared under IAS 34 and are not statutory accounts. Renalytix is moving its accounting reference date to 31 …

Ankur Sharma | 29 October 2026

GSK (LSE:GSK) lifts Q3 turnover 4% to £8.9bn and backs upper-half 2026 growth guidance

GSK published its third-quarter results on 28 October 2026. Turnover for the quarter rose 4% to £8,887m, or 5% at constant exchange rates (CER). For the first nine months, turnover reached £24,925m, also up 4% (5% CER).

Ankur Sharma | 29 October 2026

FTSE 100 Watch: Why Smith & Nephew plc (LSE:SN.) Is Drawing Investor Attention as 2026 Outlook Takes Shape

Smith & Nephew plc (LSE:SN.) remains on the radar as investors assess medical devices and orthopaedics against changing economic conditions.

Ankur Sharma | 29 October 2026

FTSE 100 Spotlight: Can AstraZeneca PLC (LSE:AZN) Navigate Quarterly results expected on 30 october?

• Investors are monitoring oncology pipeline, drug launches and operating guidance; the direction of those indicators will influence the next reassessment.

Ankur Sharma | 29 October 2026

FTSE 100 Spotlight: Can GSK plc (LSE:GSK) Navigate 28 october quarterly results?

• Investors are monitoring vaccines, specialty medicines and research spending; the direction of those indicators will influence the next reassessment.

Ankur Sharma | 29 October 2026

FTSE 100 Spotlight: Can Haleon PLC (LSE:HLN) Navigate Consumer health demand?

• Investors are monitoring organic sales, product innovation and cash conversion; the direction of those indicators will influence the next reassessment.

Ankur Sharma | 29 October 2026
Support

Hi! How can we help you today?

Loading…